All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drtoomertalks on TikTok · 180s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drtoomertalks's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hello, it's me, Dr. Tumor, Family Medicine and Community Health Physician and Weight Health Specialist.
  2. 0:06I just want to say this, please, if you are taking a compounded GLP1, semaglutide, tresipatide, please know your dose in milligrams.
  3. 0:17Not in units, insulin's prescribing units, not GLP1.
  4. 0:23Know your dose in milligrams, not milliliters.
  5. 0:27Because milliliters means nothing if you don't know how many milligrams per milliliter is in your medication.
  6. 0:35Know it in milligrams, period.
  7. 0:39If you don't know it in milligrams, you have no idea what you're getting.
  8. 0:43And not all compound pharmacies are made equally.
  9. 0:47The one I use, I trust, I do not trust them all.
  10. 0:50I have family members using the one I have a relationship with.
  11. 0:54I have friends using the one that have a relationship.
  12. 0:57I will use them if I ever lose access to my GLP1.
  13. 1:02That's not saying you should switch over.
  14. 1:05I'm just simply saying, when you are giving your dose, you know how much in milligrams you're taking.
  15. 1:12Look in my link tree.
  16. 1:14I have written every single one out.
  17. 1:17So there's the titration doses for every single GLP1 on the market.
  18. 1:20It's your free printed out. Look at it.
  19. 1:22And ask whoever is giving you your medication, which one you're on.
  20. 1:27What dose you're on.
  21. 1:29Again, not in units, not in milliliters, not in lines on a syringe in milligrams.
  22. 1:37Because if you don't know what you're taking in milligrams, you have no idea if you're an effective dose.
  23. 1:42You have no idea how to switch over if you go from one compound pharmacy to another.
  24. 1:46Or if you decide if you are getting gained access to a manufacturer GLP1, you have no idea what dose you're on.
  25. 1:53Not how many times you've been titrated up because what I'm seeing is the titration doses aren't even accurate.
  26. 2:01I'm, you know, in doing the math based on milligrams per milliliters, a number of milliliters that people are taking,
  27. 2:08it still doesn't equal any dose of the manufacturer.
  28. 2:13So I can't figure, I mean, really, please.
  29. 2:17Because there are people out there who know this is making them a whole lot of money and they're just not always scrupulous.
  30. 2:23And they may not know what they're doing.
  31. 2:26So just know doses, you know, for semaglutide, if it's Ozempic, it's .25, .5, 1, 2.
  32. 2:36If it is wagovi, it's .25, .5, 1, 1.7, 2.4.
  33. 2:42So if it's ozempicitide, ronjaro, it is 2.5, 5, 7.5, 10, 12.5, 15.
  34. 2:50Those are the milligrams.
  35. 2:52And if you don't know your dose by milligrams, find out and find out now.
  36. 2:56All right. That's my PSA for the day.

@drtoomertalks's dosing advice for compounded GLP-1s checked

Dr.ToomerTalks

TikTok creator

35.9K viewsWatch on TikTok

Quick answer

Compounded semaglutide and tirzepatide are administered as subcutaneous injections, typically dosed in milligrams using a volume drawn from a multi-dose vial. Because vial concentrations vary across compounding pharmacies, patients who dose by volume or syringe lines without knowing the milligrams-per-milliliter concentration of their specific product cannot reliably verify their actual milligram intake. The FDA issued safety communications in 2023 and 2024 documenting real-world dosing errors linked to unit confusion and concentration variability in compounded GLP-1 products.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @drtoomertalks's dosing advice for compounded GLP-1s checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@drtoomertalks's dosing advice for compounded GLP-1s checked" from Dr.ToomerTalks. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Compounded semaglutide and tirzepatide are administered as subcutaneous injections, typically dosed in milligrams using a volume drawn from a multi-dose vial.

The reason this review is not generic is the source wording and the canonical claim label "glp1 if you are taking compounded semaglutide or terzepatide pl." In this clip, the useful excerpt is: "Hello, it's me, Dr." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

A 2024 JAMA Internal Medicine analysis (Downing et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Compounded semaglutide and tirzepatide are administered as subcutaneous injections, typically dosed in milligrams using a volume drawn from a multi-dose vial.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Compounded semaglutide and tirzepatide are administered as subcutaneous injections, typically dosed in milligrams using a volume drawn from a multi-dose vial. Because vial concentrations vary across compounding pharmacies, patients who dose by volume or syringe lines without knowing the milligrams-per-milliliter concentration of their specific product cannot reliably verify their actual milligram intake. The FDA issued safety communications in 2023 and 2024 documenting real-world dosing errors linked to unit confusion and concentration variability in compounded GLP-1 products.
  • The FDA issued specific safety communications in 2023 and 2024 warning that compounded semaglutide has been involved in dosing errors, often tied to unit confusion and concentration variability.
  • A 2024 JAMA Internal Medicine analysis (Downing et al.) found compounded semaglutide products with inconsistent concentrations, meaning volume-based dosing alone is an unreliable way to confirm your actual milligram intake.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The FDA issued specific safety communications in 2023 and 2024 warning that compounded semaglutide has been involved in dosing errors, often tied to unit confusion and concentration variability.
  • A 2024 JAMA Internal Medicine analysis (Downing et al.) found compounded semaglutide products with inconsistent concentrations, meaning volume-based dosing alone is an unreliable way to confirm your actual milligram intake.
  • FDA-approved titration schedules are: Ozempic 0.25-2 mg, Wegovy 0.25-2.4 mg, Mounjaro/Zepbound 2.5-15 mg. These are reference points for a prescriber conversation, not a self-dosing guide.
  • Compounded GLP-1 products are not FDA-approved and are not held to the same bioequivalence standards as branded drugs. They entered the market through a drug shortage provision that is subject to ongoing regulatory review.
  • Switching between compounded pharmacies, or from compounded to branded products, requires a prescriber to reassess dosing. Volume-to-volume substitution is not safe without knowing each product's specific concentration.
  • GLP-1 doses use milligrams. Insulin doses use units. These are different drug classes with different measurement systems. Never apply insulin unit logic to a GLP-1 product.
  • Knowing your dose in milligrams is necessary for safety and continuity, but effective dosing is a clinical determination that depends on individual tolerability and response, not just matching a manufacturer titration schedule.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drtoomertalks actually say?

The core message here is straightforward: if you are taking compounded semaglutide or tirzepatide, you should know your dose in milligrams, not in units, milliliters, or syringe lines. The doctor states plainly that "if you don't know what you're taking in milligrams, you have no idea if you're on an effective dose." She also lists the FDA-approved titration schedules for Ozempic, Wegovy, and Mounjaro/Zepbound as reference points. The secondary argument is that compounded pharmacy dosing does not always match manufacturer dosing when you do the math, and that patients switching between compounded and brand products could be flying blind without milligram-based knowledge.

She is not prescribing doses or claiming compounded drugs are equivalent to branded ones. She is making a patient safety argument about unit literacy. That is an important distinction.

Does the science back this up?

Yes, substantially. Dosing confusion in GLP-1 therapy is a documented patient safety concern, not a hypothetical one. The FDA issued a safety communication in 2023 specifically warning about medication errors with compounded semaglutide, citing cases where patients received doses in units more commonly associated with insulin, leading to dosing errors of up to tenfold. The agency repeated these warnings in 2024 as compounded GLP-1 use expanded.

A 2024 analysis in JAMA Internal Medicine (Downing et al.) found significant variability in compounded semaglutide products available online, with some products failing to meet labeled concentrations. If a product's concentration differs from what's assumed, then dosing by volume alone produces unpredictable actual milligram delivery. The math point the doctor raises, that titration doses "don't even equal any dose of the manufacturer," is consistent with this evidence. Knowing the milligrams per milliliter concentration of your specific compounded vial is, in fact, the only way to verify you are taking a meaningful dose.

What did they get wrong (or right)?

Mostly right, with a few rough edges. The titration schedules she cites are accurate for the branded products. Ozempic starts at 0.25 mg, Wegovy at 0.25 mg up to 2.4 mg, and tirzepatide (Mounjaro/Zepbound) from 2.5 mg to 15 mg. Those numbers match FDA-approved labeling.

One issue worth flagging: she conflates the concept of knowing your milligram dose with knowing whether you are on an "effective dose." These are related but not the same thing. Effective dosing in GLP-1 therapy is highly individual. Tolerability, weight loss response, and side effect burden all influence where a patient lands. A physician should be determining effective dosing, not a patient cross-referencing a printout. The milligram-literacy argument is valid for safety and continuity purposes. Framing it as the sole determinant of efficacy oversimplifies the clinical picture.

Her note that "not all compound pharmacies are made equally" is accurate and, if anything, understated. FDA inspections have found sterility and potency failures at some compounding facilities.

What should you actually know?

If you are using compounded semaglutide or tirzepatide, three things matter for your safety. First, confirm the concentration of your vial in milligrams per milliliter with your prescriber or pharmacist before drawing any dose. Second, never convert GLP-1 doses using insulin unit logic. The two drug classes use entirely different measurement systems. Third, if you transition from a compounded product to a branded one, or between compounded pharmacies, your prescriber needs to reassess your dose from scratch. Do not assume volume-to-volume equivalence.

It is also worth knowing that compounded GLP-1 products are not FDA-approved and are not required to demonstrate the same bioequivalence standards as branded drugs. The FDA placed semaglutide on its drug shortage list, which created a legal window for compounding. That window has been contested and is subject to ongoing regulatory change. Patients using these products should stay in contact with a licensed prescriber, not manage titration based on social media printouts alone, however well-intentioned.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr.ToomerTalks · TikTok creator

35.9K views on this video

If you are taking compounded #semaglutide or #terzepatide PLEASE know your #GLP1dose is milliGRAMS - Not units, not milliliters, not suringe lines - MILLIGRAMS otherwise you have no idea if you are

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the fda?

The FDA issued specific safety communications in 2023 and 2024 warning that compounded semaglutide has been involved in dosing errors, often tied to unit confusion and concentration variability.

What does the video say about a 2024 jama internal medicine analysis (downing et al.) found?

A 2024 JAMA Internal Medicine analysis (Downing et al.) found compounded semaglutide products with inconsistent concentrations, meaning volume-based dosing alone is an unreliable way to confirm your actual milligram intake.

What does the video say about fda-approved titration schedules?

FDA-approved titration schedules are: Ozempic 0.25-2 mg, Wegovy 0.25-2.4 mg, Mounjaro/Zepbound 2.5-15 mg. These are reference points for a prescriber conversation, not a self-dosing guide.

What does the video say about compounded glp-1 products?

Compounded GLP-1 products are not FDA-approved and are not held to the same bioequivalence standards as branded drugs. They entered the market through a drug shortage provision that is subject to ongoing regulatory review.

What does the video say about switching between compounded pharmacies,?

Switching between compounded pharmacies, or from compounded to branded products, requires a prescriber to reassess dosing. Volume-to-volume substitution is not safe without knowing each product's specific concentration.

What does the video say about glp-1 doses use milligrams. insulin doses use units. these?

GLP-1 doses use milligrams. Insulin doses use units. These are different drug classes with different measurement systems. Never apply insulin unit logic to a GLP-1 product.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by Dr.ToomerTalks, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.